CAS 71119-11-4

Bucindolol

Description:

Bucindolol is a non-selective beta-adrenergic antagonist, primarily used in the treatment of hypertension and heart failure. It is characterized by its ability to block beta-1 and beta-2 adrenergic receptors, which helps to reduce heart rate and myocardial contractility, ultimately lowering blood pressure. Bucindolol also exhibits intrinsic sympathomimetic activity, meaning it can partially stimulate beta receptors while blocking them, which may lead to fewer side effects compared to other beta-blockers. The chemical structure of Bucindolol includes a phenolic hydroxyl group and a secondary amine, contributing to its pharmacological properties. It is typically administered orally and has a moderate bioavailability. Bucindolol's efficacy and safety profile make it a valuable option in managing cardiovascular conditions, although its use may be limited by potential side effects such as fatigue, dizziness, and respiratory issues in susceptible individuals. As with any medication, it is essential to consider patient-specific factors and contraindications when prescribing Bucindolol.

Formula: C₂₂H₂₅N₃O₂

InChI: InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3

InChI key: InChIKey=FBMYKMYQHCBIGU-UHFFFAOYSA-N

SMILES: C(C(NCC(COC1=C(C#N)C=CC=C1)O)(C)C)C=2C=3C(NC2)=CC=CC3

Synonyms:

• 2-(2-Hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile
• 2-(2-hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile
• <span class="text-smallcaps">DL</span>-Bucindolol
• Benzonitrile, 2-(2-hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-
• Bucindolol [INN:BAN]
• Bucindololum
• Bucindololum [INN-Latin]
• Mj 13105-1
• Unii-E9Uo06K7Ce
• Bucindolol
• DL-Bucindolol

2-(3-((1-(1H-Indol-3-yl)-2-methylpropan-2-yl)amino)-2-hydroxypropoxy)benzonitrile

CAS: 71119-11-4

Formula: C₂₂H₂₅N₃O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 363.4528

Ref: IN-DA005NYX

Bucindolol

CAS: 71119-11-4

Bucindolol

Purity: ≥98%

Molecular weight: 363.45g/mol

Ref: 54-BUP21848

Bucindolol

Controlled Product

CAS: 71119-11-4

Applications Bucindolol is a high-affinity, competitive beta blocker used in the treatment of congestive heart failure and hypertension.
References Hershberger, R., et al.: J. Cardiovasc. Pharm., 15, 959 (1990); Pollock, S., et al.: Am. J. Cardiol., 66, 603 (1990); Rotmensch, H., et al.: Am. J. Cardiol., 54, 353 (1984)

Formula: C₂₂H₂₅N₃O₂

Color and Shape: Neat

Molecular weight: 363.45

Ref: TR-B689430

Bucindolol

CAS: 71119-11-4

Bucindolol (BMY 13105) is a novel and potent β1-adrenergic receptor blocker that mediates vasodilation and can be used to study chronic heart failure.

Formula: C₂₂H₂₅N₃O₂

Purity: 99.9%

Color and Shape: Solid

Molecular weight: 363.45

Ref: TM-T10631

Bucindolol-D5

Controlled Product

CAS: 71119-11-4

Formula: C₂₂D₅H₂₀N₃O₂

Color and Shape: Neat

Molecular weight: 368.484

Ref: TR-B689432

Bucindolol

CAS: 71119-11-4

Bucindolol is a non-selective beta-blocker, which is a synthetic compound with affinity for beta-adrenergic receptors. These receptors are part of the autonomic nervous system and play a crucial role in cardiovascular function. Bucindolol acts by competitively antagonizing beta-1 and beta-2 adrenergic receptors, which results in decreased heart rate, myocardial contractility, and peripheral vascular resistance.

Formula: C₂₂H₂₅N₃O₂

Purity: Min. 95%

Molecular weight: 363.46 g/mol

Ref: 3D-WCA11911